CD7 CAR-T: a bridge to transplant in AML

被引：0
|
作者：
Mamonkin, Maksim [1 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
来源：
BLOOD | 2025年 / 145卷 / 10期
关键词：
THERAPY; 1ST-IN-HUMAN; CELLS;
D O I：
10.1182/blood.2024027442
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Lu et al1 report early results from a phase 1 study of autologous CD7 chimeric antigen receptor-modified T cells (CD7 CAR-T) in patients with acute myeloid leukemia (AML). The authors describe the safety and preliminary efficacy of CD7 CAR-T, which induced disease remission in most patients. However, the responses were durable only in those who received subsequent allogeneic hematopoietic stem cell transplant (alloHSCT).
引用
收藏
页码：995 / 996
页数：2
相关论文
共 50 条
  • [21] Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
    Yu Lu
    Ying Liu
    Shupeng Wen
    Na Kuang
    Xuejun Zhang
    Jianqiang Li
    Fuxu Wang
    Journal of Translational Medicine, 20
  • [22] Allogeneic CD7-CAR T cells to bridge the gap?
    Velasquez, M. Paulina
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (03): : 139 - 140
  • [23] CD7 CAR for the Treatment of Acute Myeloid and Lymphoid Leukemia
    Silva, Diogo
    Tashiro, Haruko
    Srinivasan, Madhuwanti
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2016, 128 (22)
  • [24] Depletion of Tregs from CD4+ CAR-T cells enhances the tumoricidal effect of CD8+ CAR-T cells in anti-CD19 CAR-T therapy
    Sun, Yunyan
    Liu, Jinyan
    Zhan, Dong
    Wei, Jia
    Li, XianShi
    Zhang, Rui
    Duan, Ci
    Zhang, Disi
    Tang, Xiaorong
    Lin, Tuo
    Li, Limei
    Lai, Xun
    FEBS JOURNAL, 2024,
  • [25] CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
    Shiqi Li
    Xinxin Wang
    Lin Liu
    Jia Liu
    Jun Rao
    Zhongtao Yuan
    Li Gao
    Yu Li
    Le Luo
    Gui Li
    Zhimin Li
    Sheng Li
    Jiaping He
    Lihua Zhang
    Lvzhe Chen
    Wenhui Huang
    Ping Yin
    Chunmin Li
    Xiaoping Li
    Youcheng Wang
    Yancheng Dong
    Dingsong Zhang
    Qingying Zang
    Yingnian Chen
    Lianjun Shen
    Wenling Li
    Wei Cao
    Xi Zhang
    Sanbin Wang
    Leukemia, 2023, 37 : 2176 - 2186
  • [26] VENETOCLAX, CHIDAMIDE, AND DECITABINE AS A BRIDGING THERAPY IN RELAPSED/REFRACTORY T LYMPHOBLASTIC CELL LYMPHOMAS WITH LARGE MEDIASTINAL MASSES PRIOR TO CD7 CAR-T CELL THERAPY
    Huang, Lefu
    Zhang, Xian
    Lu, Peihua
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 444 - 445
  • [27] 不表达CD7的CAR-T细胞或能更好地治疗急性淋巴细胞白血病
    Freiwan A
    生物医学工程与临床, 2022, 26 (05) : 645 - 645
  • [28] CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies
    Li, Shiqi
    Wang, Xinxin
    Liu, Lin
    Liu, Jia
    Rao, Jun
    Yuan, Zhongtao
    Gao, Li
    Li, Yu
    Luo, Le
    Li, Gui
    Li, Zhimin
    Li, Sheng
    He, Jiaping
    Zhang, Lihua
    Chen, Lvzhe
    Huang, Wenhui
    Yin, Ping
    Li, Chunmin
    Li, Xiaoping
    Wang, Youcheng
    Dong, Yancheng
    Zhang, Dingsong
    Zang, Qingying
    Chen, Yingnian
    Shen, Lianjun
    Li, Wenling
    Cao, Wei
    Zhang, Xi
    Wang, Sanbin
    LEUKEMIA, 2023, 37 (11) : 2176 - 2186
  • [29] Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial
    Lu, Peihua
    Liu, Ying
    Yang, Junfang
    Zhang, Xian
    Yang, Xiao
    Wang, Hui
    Wang, Lin
    Wang, Qinglong
    Jin, David
    Li, Jianqiang
    Huang, Xiaojun
    BLOOD, 2022, 140 (04) : 321 - 334
  • [30] Biomarkers as targets for CAR-T/NK cell therapy in AML
    Ruonan Shao
    Zijian Li
    Honglei Xin
    Suyu Jiang
    Yilin Zhu
    Jingan Liu
    Rong Huang
    Kailin Xu
    Xiaofeng Shi
    Biomarker Research, 11
12345